Phase 3 Stroke Trial, Recruiting NCT07430956 Sponsor: Regeneron Pharmaceuticals Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT07430956
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have atrial fibrillation (an irregular heartbeat) or atrial flutter that is not caused by a temporary or treatable condition
  • People who are at moderate to high risk of having a stroke, based on a medical scoring system that considers factors such as heart failure, high blood pressure, age, diabetes, previous stroke or blood clots, and blood vessel disease
  • People whose doctor and care team have jointly decided that the risks of taking blood-thinning medication are greater than the benefits, making that type of medication unsuitable for them

Who may not be able to join:

  • People who have an artificial mechanical heart valve (note: a certain type of heart valve procedure called transcatheter aortic valve replacement does not appear to count as an exclusion)
  • People who have had a stroke caused by a blocked blood vessel within 2 days before entering the trial
  • People who have high blood pressure that is ongoing and not under control, as determined by the treating doctor
  • People who have had bleeding in or around the brain within 30 days before entering the trial
  • People whose life expectancy is estimated to be less than 12 months
  • People who have previously taken part in a clinical study involving a type of medication called a Factor XI inhibitor
  • Additional criteria set out in the trial protocol may also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
3 April 2026
Est. completion
28 March 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to first occurrence of ischemic stroke or systemic embolism; Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov